Ποια είναι η τιμή για Agile Therapeutics, Inc. (AGRX)

Η τιμή για Agile Therapeutics, Inc. (AGRX) είναι $1.51

Ποια είναι η κεφαλαιοποίηση αγοράς για Agile Therapeutics, Inc. (AGRX)

Η κεφαλαιοποίηση αγοράς για Agile Therapeutics, Inc. (AGRX) είναι $1.12M

Agile Therapeutics, Inc. (AGRX) Τιμή και Κεφαλαιοποίηση Αγοράς

Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.

Η τιμή για AGRX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$7,367,550 $1.12M	NVDA	$5.452T	+487,917,105.32%
$6,067,727 $1.12M	AAPL	$4.490T	+401,836,151.34%
$5,624,997 $1.12M	GOOG	$4.162T	+372,516,274.07%
$4,968,139 $1.12M	MSFT	$3.676T	+329,015,719.26%
$3,828,520 $1.12M	AMZN	$2.833T	+253,544,246.28%

Η τιμή για AGRX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$7,367,550 $1.12M